Identifying breast cancer patients who can be spared chemotherapy, evidence from recent studies

Identifying breast cancer patients who can be spared chemotherapy, evidence from recent studies

EMJ

3 years
596 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
Report 0 0
Category:
Description:
The Oncotype DX® 21-gene Recurrence Score® result stratifies patients with breast cancer into low-, intermediate- and high-risk groups that correspond to the likelihood of recurrence after the initial diagnosis. At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg Gluz, MD, from the West German Study Group, Mönchengladbach, Germany, discusses the evidence of the predictive value of the Recurrence Score® result to guide decision making for adjuvant chemotherapy.

This content is supported by Genomic Health, Inc.
Up Next Autoplay